Get In Touch
Have any questions or comments about the content you see on this page?
March 11, 2021
As scientific pioneers, corporate leaders and global citizens, Alnylam has long been committed to using our business as a force for good beyond our core mission of developing innovative medicines. It’s in our employees' “RNA” to strive to make an impact and they passionately embrace the opportunity to influence and create positive change in the world.
And yet, in an increasingly complex world and as our company continues to rapidly grow, we recognized the need to take a holistic, integrated and more intentional approach to Corporate Responsibility. Doing so, we determined, would allow us to ensure that our actions reflect our Core Values and to be even more deliberate in how we understand, manage, and communicate Alnylam’s impact.
So in early 2020, we began a process of assessment and introspection to set priorities for Corporate Responsibility and most importantly, establish the organizational structures necessary to ensure that our actions will match our intentions.
Today, we are proud to reveal the results of that process in our new Corporate Responsibility theme – “Accepting Challenges to Improve the Health of Humanity” – and our first Corporate Responsibility Summary.
We have an exciting CR journey ahead, beginning with more clearly defining our path and setting goals and targets to propel progress. We realize this is a first step and we have considerable work ahead of us. Moving forward, we are committed to increased transparency by continuously sharing more data, initiatives, and progress. Our CR theme, "Accepting Challenges to Improve the Health of Humanity," is aligned with our corporate values and mission, and is intended to inspire us to work toward this noble pursuit each day.” – John Maraganore, CEO of Alnylam
Accompanying our CR theme is a formalized strategic framework for our Corporate Responsibility activities which provides guidance around how we can implement new and advance existing initiatives around five interconnected, stakeholder-related focus areas:
Our Corporate Responsibility Summary provides more details on the specific actions we're taking and intend to take in 2021 and beyond. We will report out annually on our efforts and progress, holding our organization accountable and being transparent with our findings.
This very important step is as essential to our growing business as the tireless scientific innovation and passion of our people that enables it. It's a step consistent with Alnylam's legacy of setting ambitious goals, and we are up for the challenge. As always, we say "challenge accepted!"
The following content may not be associated with Alnylam Pharmaceuticals.
Links to all outside sites are provided as a reference for our visitors.
Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.Proceed to Site